Going with the Flow and Beyond: Understanding Benign Blood Disorders and Their Underlying Mechanisms

A special issue of Cells (ISSN 2073-4409).

Deadline for manuscript submissions: 31 December 2026 | Viewed by 1970

Special Issue Editor


E-Mail Website
Guest Editor
Versiti Blood Research Institute, Milwaukee, WI, USA
Interests: sickle cell disease; hemolysis; blood transfusion-induced organ damage; cell-free hemoglobin clearance

Special Issue Information

Dear Colleagues,

Benign hematological disorders, including sickle cell disease, polycythemia vera, hemophilia, and thalassemia, represent a major group of blood disorders that affect a large number of people worldwide. Beyond their clinical severity, these benign blood disorders have a significant impact on our understanding of the basic, molecular, and physiological aspects of blood cell structures, functions, and regulation. This Special Issue will collect original research and review articles on the molecular mechanisms behind benign blood disorders. We welcome the submission of articles focused on red blood cell structures, functions, and regulation, heme iron and hemoglobin clearance, and iron overload-associated organ damage. Additional possible sub-themes for papers include endothelial cell senescence, vascular aging, and the regulation of blood vessel formation.

Dr. Tirthadipa Pradhan-Sundd
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • benign blood disorders
  • sickle cell disease
  • red blood cells
  • hemoglobin
  • heme
  • iron overload
  • organ damage
  • hemophilia
  • thalassemia
  • anemia
  • blood vessels
  • vascular aging
  • endothelial cells

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

32 pages, 2044 KB  
Review
Rethinking Sickle Cell Disease as a Systemic Vasculopathy
by Mariana DuPont, Najibah A. Galadanci, Rushil V. Patel, Jeffrey Lebensburger and Julie Kanter
Cells 2026, 15(4), 326; https://doi.org/10.3390/cells15040326 - 10 Feb 2026
Viewed by 1545
Abstract
Sickle cell disease (SCD) is the most common inherited clinically relevant blood disorder. Although a deceptively simple monogenetic disorder, the associated complications have multiple downstream effects. In this review, we explore the many facets of SCD, with a particular focus on its impact [...] Read more.
Sickle cell disease (SCD) is the most common inherited clinically relevant blood disorder. Although a deceptively simple monogenetic disorder, the associated complications have multiple downstream effects. In this review, we explore the many facets of SCD, with a particular focus on its impact on the vascular system. Despite progress in understanding the underlying mechanisms of SCD, including Hemoglobin S polymerization, microvascular occlusion, and inflammation, there are still many questions surrounding the condition, especially predicting which affected individuals will acquire specific complications in order to personalize treatments. While current standard of care treatments, including hydroxyurea and chronic red blood cell transfusions, have been proven to be disease-modifying, newer therapies like crizanlizumab and voxelotor have only proven to manage symptoms. Newer gene therapies have been approved; however, it is not clear what impact these will have long-term on the end-organ complications of SCD. There is still a significant need to understand how we optimize and personalize therapies to improve outcomes for patients. This review highlights the importance of recognizing SCD as a vascular disease to understand its multi-organ complications and heterogeneity of effects. Full article
Show Figures

Figure 1

Back to TopTop